CompletedPhase 2NCT01979536
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Eric J LoweChildren's Oncology Group
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 137 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2013 – 2024
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01979536 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE3NCT06724237Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyEastern Cooperative Oncology Group
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
See all trials for ALK-negative anaplastic large cell lymphoma →